{
    "title": "114_s2067",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Ensuring Useful Research \nExpenditures is Key for Alzheimer's Act'' or the ``EUREKA Act''.\n\nSEC. 2. AUTHORIZATION OF NATIONAL ALZHEIMER'S AND DEMENTIA RESEARCH \n              BREAKTHROUGH PRIZE COMPETITIONS.\n\n    Part B of title IV of the Public Health Service Act (42 U.S.C. 284 \net seq.) is amended by adding at the end the following:\n\n``SEC. 409K. NATIONAL ALZHEIMER'S AND DEMENTIA RESEARCH BREAKTHROUGH \n              PRIZE COMPETITIONS.\n\n    ``(a) In General.--The Director of NIH, in consultation with the \nDirector of the National Science Foundation, the Director of the \nDefense Advanced Research Projects Agency, the Commissioner of Food and \nDrugs, the Director of the Intelligence Advanced Research Projects \nActivity, and the heads of any other appropriate Federal agencies that \nhave experience in prize competitions, shall establish prize \ncompetitions. The competitions shall be designed to achieve high-\npriority breakthroughs to achieve the national goals of preventing and \ntreating Alzheimer's disease by 2025, enhancing quality and efficiency \nof care for individuals with Alzheimer's disease, and expanding \nsupports for individuals with Alzheimer's disease and the family \ncaregivers of such individuals.\n    ``(b) EUREKA Prize Competitions.--\n            ``(1) In general.--The Director of NIH, in consultation \n        with the Director of the National Science Foundation, the \n        Director of the Defense Advanced Research Projects Agency, the \n        Commissioner of Food and Drugs, the Director of the \n        Intelligence Advanced Research Projects Activity, and the heads \n        of any other appropriate Federal agencies that have experience \n        in prize competitions, and when appropriate, in coordination \n        with private organizations, shall establish EUREKA prize \n        competitions to accelerate breakthroughs in the area of \n        Alzheimer's disease and dementia that lead to the attainment of \n        critical milestones set forth in the competitions. The \n        competitions may be in any of the following areas:\n                    ``(A) Identification and validation of non-invasive \n                biomarkers to inform therapeutic targeting.\n                    ``(B) Identification of scalable, non-invasive \n                means of early detection and diagnosis of Alzheimer's \n                disease.\n                    ``(C) Repurposing of a drug approved by the Food \n                and Drug Administration as a disease-modifying \n                treatment for Alzheimer's disease.\n                    ``(D) Innovations, including technological or \n                telemedicine, to improve care of individuals with \n                Alzheimer's disease or dementia and to ease the burden \n                of caregiving for such individuals, including cost \n                burdens.\n                    ``(E) Breakthroughs to overcome a significant \n                scientific barrier to understanding the pathology of \n                Alzheimer's disease.\n                    ``(F) Other Alzheimer's disease and dementia needs, \n                as appropriate and as determined by the Advisory \n                Council described in subsection (c).\n                    ``(G) Other areas, as the Director of NIH \n                determines appropriate.\n            ``(2) Publication.--The Director of NIH shall publish each \n        competition that is offered in the Federal Register, including \n        the specific award amounts offered, applicable deadlines, and \n        other eligibility criteria.\n            ``(3) Eligibility.--To be eligible to win a prize under \n        this section, an individual or private organization--\n                    ``(A) shall have registered to participate in the \n                competition under any rules promulgated by the Director \n                of NIH under paragraph (2);\n                    ``(B) shall have complied with all the requirements \n                under this section;\n                    ``(C) in the case of a private organization, shall \n                be incorporated in and maintain a primary place of \n                business in the United States, and in the case of an \n                individual, whether participating singly or in a group, \n                shall be a citizen or permanent resident of the United \n                States, unless the Director of NIH waives such \n                requirement with respect to an organization or \n                individual; and\n                    ``(D) may not be a Federal entity or Federal \n                employee acting within the scope of their employment.\n    ``(c) Advisory Council.--Not later than 1 year after the date of \nenactment of the EUREKA Act, the Director of NIH shall convene an \nAdvisory Council of nongovernmental experts in Alzheimer's disease and \ndementia to devise development of EUREKA prize competitions under \nsubsection (b). The council shall be comprised of 8 members, \nincluding--\n            ``(1) 2 experts from private organizations with expertise \n        in managing multi-faceted prize competitions;\n            ``(2) 2 experts in Alzheimer's disease and dementia \n        biomedical research;\n            ``(3) 2 experts in Alzheimer's disease and dementia therapy \n        development, including individuals with expertise in designing \n        and executing human clinical trials; and\n            ``(4) 2 individuals from the caregiver or patient advocacy \n        community.\n    ``(d) Evaluation of Submissions.--The Director of NIH, in \nconsultation with the Advisory Council, shall appoint a panel of \njudges, from within or outside the National Institutes of Health, \nincluding from the private sector, to review and evaluate all \nsubmissions for EUREKA competitions. The judging panel shall forward \nrecommendations to the Director of NIH and the Advisory Council. The \nDirector of NIH shall evaluate all submissions recommended by the \njudging panel and select submissions for which the prize shall be \nawarded. In reviewing submissions and selecting awardees, the Director \nof NIH may seek technical assistance and expertise from other Federal \nagencies or external sources, as appropriate.\n    ``(e) Administering the Competitions.--The Director of NIH may \nenter into an agreement with a private organization to administer prize \ncompetitions, subject to the provisions of this section.\n    ``(f) Applicability of Other Provisions.--Subsections (e), (h), \n(i), and (j) of section 24 of the Stevenson-Wydler Technology \nInnovation Act of 1980 shall apply to this section. In applying such \nsubsection (h) to this section, the reference to subsection (g) shall \nbe deemed to be a reference to subsection (b) of this section. \nParagraphs (2) and (3) of subsection (k) of section 24 of the \nStevenson-Wydler Technology Innovation Act of 1980 shall apply to the \nappointment and functioning of the panel of judges described in \nsubsection (d).\n    ``(g) Exemption From FACA.--The Federal Advisory Committee Act (5 \nU.S.C. App.) shall not apply to the advisory council established under \nsubsection (c) or the judging panel appointed under subsection (d).\n    ``(h) Private Organizations.--In this section, the term `private \norganizations' means nongovernmental entities, including nonprofit and \nfor-profit entities.\n    ``(i) Funding.--\n            ``(1) In general.--Support for a prize competition under \n        this section, including financial support for the design and \n        administration of a prize competition or monetary contributions \n        or gifts of property for a prize purse, may consist of Federal \n        appropriated funds, funds provided by private organizations, \n        and individuals. The Director of NIH may solicit and accept \n        funds from other Federal agencies, from private organizations, \n        and individuals to support such prize competitions. The \n        Director of NIH may not give any special consideration to any \n        individual or private organization in return for a donation.\n            ``(2) Authorization of appropriations.--To carry out this \n        section, there are authorized to be appropriated not more than \n        $10,000,000, for each of fiscal years 2017 through 2021. Any \n        funds appropriated under this paragraph shall remain available \n        until September 30, 2025.\n            ``(3) Clarification.--Any funds made available through this \n        section shall supplement, not supplant, other funding made \n        available for research on Alzheimer's disease and related \n        dementia.''."
}